|Bid||17.15 x 4000|
|Ask||30.20 x 1800|
|Day's Range||21.60 - 22.25|
|52 Week Range||11.93 - 25.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.22|
Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.
NEW YORK, June 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
GI Partners is buying two medical-storage companies to take advantage of the growing reproductive sciences field. GI is also buying California Cryobank, a donor sperm and egg bank, from health-care investors Longitude Capital and NovaQuest Capital, for an undisclosed amount. California Cryobank’s donor sperm and egg banks have worked with more than 75,000 families since 1977.
LOS ANGELES, June 15, 2018 /PRNewswire/ -- California Cryobank, the world's leading donor sperm and donor egg bank, announced today that it has signed a definitive agreement for GI Partners, a private equity investment firm, to acquire the company from leading healthcare investors Longitude Capital and NovaQuest Capital. In a separate transaction announced today, GI Partners has also entered into a definitive agreement with AMAG Pharmaceuticals, Inc. (AMAG) to acquire Cord Blood Registry (CBR), the world's largest stem cell collection and storage company.
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to divest Cord Blood Registry (CBR®) to GI Partners, a private equity investment firm, for $530 million in an all cash sale. “The divestiture of CBR is an important step as we execute on AMAG's strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAG.
In today's pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and ArQule Inc. (NASDAQ: ARQL). Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday's trading session at $23.95.
AMAG Pharmaceuticals, Inc. (AMAG) and March of Dimes today announced a strategic corporate partnership focused on a shared commitment to improve maternal health and birth outcomes, as well as to reduce health inequities. Through the partnership, AMAG will participate in the March of Dimes Prematurity Campaign Collaborative and support the expansion of the March of Dimes’ Supportive Pregnancy Care (SPC) model, an innovative group prenatal care program. “AMAG’s commitment to support the health of patients and families encompasses far more than the therapies we offer to help moms and babies.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The Prescription Drug User Fee Act (PDUFA) date for completion of FDA review of the bremelanotide NDA is March 23, 2019.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that management will participate in the Jefferies 2018 Healthcare Conference on Tuesday, June 5th at 3:30 p.m. ET. AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.
WALTHAM, Mass., May 09, 2018-- AMAG Pharmaceuticals, Inc. today commended the recent action taken by the Centers for Medicare and Medicaid Services to clarify statutory intent of section§ 1860 D-2 of the ...
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Auris Medical Holding AG (NASDAQ: EARS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EARS as the Company's latest news hit the wire. On May 04, 2018, the Switzerland-based biopharmaceutical Company announced that the article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, the Company's investigational treatment for acute inner ear hearing loss, was published in Hearing Research, one of the leading journals in the otorhinolaryngology field. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published.
The Waltham, Massachusetts-based company said it had a loss of $1.59 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Strong first quarter execution with two FDA approvals and submission of a new drug application. Conference call scheduled for 8:00 a.m. ET today. WALTHAM, Mass., May 03, 2018-- AMAG Pharmaceuticals, Inc. ...
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of J. Alan Butcher as executive vice president and chief business officer effective immediately. In his role at AMAG, Mr. Butcher is responsible for leading the company’s overall business development efforts, with a focus on continuing to expand the portfolio with products that address unmet patient needs. Additionally, he oversees the company's alliance management team, and leads the corporate strategy function in close collaboration with Mr. Heiden, the senior leadership team, and the board of directors.
I am going to run you through how I calculated the intrinsic value of AMAG Pharmaceuticals Inc (NASDAQ:AMAG) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
WALTHAM, Mass., April 27, 2018-- AMAG Pharmaceuticals, Inc. today announced that company management will participate in the following investor conferences:. Deutsche Bank Annual Health Care Conference ...
WALTHAM, Mass., April 26, 2018-- AMAG Pharmaceuticals, Inc. today announced that its first quarter 2018 financial results will be released on Thursday, May 3, 2018 before the U.S. financial markets open. ...
NEW YORK, April 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
AMAG Pharma (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRANBURY, N.J., March 26, 2018 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced today that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.